Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Godaddy Inc (GDDY) vs Viatris Inc (VTRS) Price & Performance

Godaddy IncTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

Godaddy Inc vs Viatris Inc — how do they compare? Godaddy Inc trades at $94.05 (market cap $12.09B), while Viatris Inc trades at $17.19 (market cap $19.44B). The key difference: Viatris Inc is the larger of the two by market cap, and Viatris Inc pays a 2.88% dividend while Godaddy Inc pays none. Which is the better fit depends on your goals.

GDDYVTRS
Market Cap
$12.09B$19.44B
Sector
TechnologyHealth
52-Week High
$169.40$17.39
52-Week Low
$75.07$8.74
Enterprise Value
$14.67B$31.65B
Dividend Yield
2.88%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Godaddy Inc

GoDaddy (GDDY) trades at $94.12, up 3.31% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong earnings beats in recent quarters, with Q2 2026 results due July 30, 2026. Fundamentals show robust profitability with a 17.32% net margin and 63.77% gross margin, though revenue growth is moderating. Analyst consensus is bullish with a $123 price target, but legal investigations pose sentiment risks.

Outlook remains positive given earnings momentum and high analyst buy ratings, but investors face near-term volatility from legal overhangs and elevated valuation multiples. The stock offers upside to consensus targets if execution continues, yet legal and competitive pressures require monitoring for sustained growth.

Viatris Inc

Viatris (VTRS) trades at $17.215, up 5.55% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3 billion in 2025 but posted a net loss of $3.51 billion, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a decision expected by December 2026. Analyst consensus leans toward Hold, with a $20 price target suggesting modest upside from current levels.

The outlook for VTRS hinges on successful pipeline execution and debt management, offering value potential if biosimilar and specialty drug launches gain traction. Key risks include persistent negative margins, high debt levels, and competitive pressures in the generics market. Investors should weigh the company's cost-cutting efforts and product diversification against its profitability challenges.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Godaddy Inc

GoDaddy is a provider of domain registration and aftermarket services, website hosting, security, design, and business productivity tools, commerce solutions, and domain registry services. The company primarily targets micro- to small businesses, website design professionals, registrar peers, and domain investors. Since acquiring payment processing platform Poynt in 2021, the company has expanded into omnicommerce solutions, including offering an online payment gateway and offline point-of-sale devices.

Read more on GDDY

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS